Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Maria Espasandin"'
Autor:
Maria Espasandin
Publikováno v:
British Journal of Neuroscience Nursing. 15:180-183
Treating multiple sclerosis (MS) with alemtuzumab involves multiple dosing cycles and long-term safety monitoring. With the NHS being under increasing financial pressure, there is the potential for gaps to form between national guidelines for MS trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba75360d4a1fe984d4b765ccfbe46ee4
https://doi.org/10.12968/bjnn.2019.15.4.180
https://doi.org/10.12968/bjnn.2019.15.4.180
Autor:
Sharmilee Gnanapavan, Özlem Yildiz, Stefania De Trane, Klaus Schmierer, Maria Espasandin, David Baker, Benjamin Turner, Cesar Alvarez-Gonzalez, Kimberley Allen-Philbey, Zhifeng Mao, Monica Marta, Tom Campion, Ashok Adams, Joela Mathews, Gavin Giovannoni
Publikováno v:
Multiple sclerosis and related disorders. 27
Background Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with progressive MS (pwPMS). Cladri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b76119e76c8d72d133aef7408acc46a4
https://pubmed.ncbi.nlm.nih.gov/30419510
https://pubmed.ncbi.nlm.nih.gov/30419510